Europe: right now in Europe, or at least here in France, we are still in the midst of the fallout of the fenfluramine class drug called Mediator, sold by Servier. European authorities were totally asleep at the switch, allowing sales to continue years after the Ahp lawsuits, plus all sorts of conflicts of interests coming out about Servier corrupting the regulatory process. Now Servier is looking awful for trying to sneak their way out of properly indemnifying claimants...
In view of this it just seems unimaginable that belviq could get approved. Plus obesity is nowhere near the issue it is in the US.
Market Data 
Markets 
AI
